Raptor's Clinical Trial for Cysteamine in Huntington's: Cause for Optimism?
Posted March 1, 2014 by LaVonne Goodman, M.D
Raptor Pharmaceutical Corp. announced some positive (though preliminary) results from the 18-month review of their Phase 2/3 clinical trial of RP103, a cysteamine drug for Huntington's disease (HD). They reported slower progression of motor impairment in those participants who had received drug compared to those who had received placebo. If these positive results hold up on further analysis and completion of the remaining 18 months of trial, this author believes we have very good reasons to be optimistic about this drug for HD.
What is this Raptor drug? Why try this drug in an HD clinical trial? And -- why might we be optimistic now?
Antipsychotics for Huntington's Disease: Are they all the same?
Posted January 13, 2014 by LaVonne Goodman, M.D.
Antipsychotic drugs are frequently prescribed for several symptoms of Huntington's disease (HD). Does it make any difference which one is used? While there is no clinical trial evidence for HD, early clinical trials in schizophrenia suggested that one is not that much better than another. However more recent reviews and studies make the important point that older ones -- like Haldol -- appear to have more unwanted side effects than the newer ones, side effects that may further impair gait, balance and cognition in HD.
Treatment Guidelines for Huntington's: Who needs them?
Posted by LaVonne Goodman M.D.
During my years as an internal medicine physician, I have used standard of care guidelines for my patients with conditions like diabetes and heart disease. Guidelines are developed by experts in each disease who
translate clinical trial evidence and/or expert experience into recommended care patterns
for use in medical offices or at the bedside. When followed, guidelines have been central to improving the
quality of care provided by all physicians whether they are specialists or